COFG Advisors LLC Takes $1.23 Million Position in Celcuity, Inc. $CELC

COFG Advisors LLC acquired a new stake in shares of Celcuity, Inc. (NASDAQ:CELC) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 12,291 shares of the company’s stock, valued at approximately $1,226,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Norges Bank purchased a new position in Celcuity in the 4th quarter worth $1,317,000. SBI Okasan Asset Management Co.Ltd. purchased a new position in Celcuity in the 4th quarter worth $660,000. Intech Investment Management LLC raised its position in Celcuity by 1.4% in the 4th quarter. Intech Investment Management LLC now owns 12,983 shares of the company’s stock worth $1,295,000 after purchasing an additional 183 shares during the period. Geode Capital Management LLC grew its holdings in Celcuity by 8.4% in the 4th quarter. Geode Capital Management LLC now owns 830,684 shares of the company’s stock worth $82,872,000 after acquiring an additional 64,213 shares during the last quarter. Finally, Integrity Alliance LLC. bought a new stake in Celcuity in the 4th quarter worth $451,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Stock Down 7.5%

CELC opened at $122.96 on Tuesday. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04. The firm has a 50 day moving average price of $123.29 and a 200-day moving average price of $111.48. Celcuity, Inc. has a twelve month low of $10.60 and a twelve month high of $151.02. The stock has a market capitalization of $6.00 billion, a price-to-earnings ratio of -31.53 and a beta of 0.09.

Celcuity (NASDAQ:CELC) last announced its earnings results on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.10. Equities research analysts forecast that Celcuity, Inc. will post -3.96 earnings per share for the current year.

Insider Buying and Selling at Celcuity

In other news, Director Richard E. Buller sold 9,000 shares of the stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.46, for a total value of $1,264,140.00. Following the sale, the director owned 6,760 shares of the company’s stock, valued at approximately $949,509.60. This represents a 57.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the completion of the sale, the director directly owned 65,000 shares in the company, valued at approximately $9,144,200. This represents a 27.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 37,000 shares of company stock valued at $5,111,950 in the last quarter. 13.33% of the stock is owned by company insiders.

Analyst Ratings Changes

CELC has been the topic of a number of recent analyst reports. Citigroup reissued a “market outperform” rating on shares of Celcuity in a report on Thursday. Wells Fargo & Company raised their price target on shares of Celcuity from $150.00 to $183.00 and gave the stock an “overweight” rating in a report on Friday, May 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $157.00 target price on shares of Celcuity in a research note on Friday, May 15th. HC Wainwright lifted their target price on shares of Celcuity from $165.00 to $185.00 and gave the company a “buy” rating in a research note on Monday, May 18th. Finally, Craig Hallum reaffirmed a “buy” rating and set a $189.00 target price on shares of Celcuity in a research note on Monday, May 4th. Eleven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $150.27.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.